DCM
KNSA icon

Driehaus Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Driehaus Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$29.4M Sell
611,398
-21,429
-3% -$949K 0.22% 151
2025
Q4 		$26.1M Sell
632,827
-21,758
-3% -$873K 0.18% 170
2025
Q3 		$25.4M Buy
654,585
+6,605
+1% +$215K 0.18% 183
2025
Q2 		$17.9M Buy
647,980
+36,702
+6% +$934K 0.14% 193
2025
Q1 		$13.6M Sell
611,278
-2,272
-0.4% -$46.8K 0.13% 203
2024
Q4 		$12.1M Sell
613,550
-117,393
-16% -$2.68M 0.1% 225
2024
Q3 		$18.3M Buy
730,943
+115,107
+19% +$2.8M 0.16% 180
2024
Q2 		$11.5M Sell
615,836
-6,704
-1% -$126K 0.11% 201
2024
Q1 		$12.3M Sell
622,540
-39,175
-6% -$765K 0.12% 217
2023
Q4 		$11.6M Buy
661,715
+157,965
+31% +$2.6M 0.14% 217
2023
Q3 		$8.75M Buy
+503,750
New +$8.49M 0.11% 227

Other funds holding KNSA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Driehaus Capital Management's KNSA Position: Q1 2026 in Review

Driehaus Capital Management reduced its Kiniksa Pharmaceuticals (KNSA) stake by 3.4% in Q1 2026, selling an estimated $949K and leaving 611,398 shares worth $29.4M. The position accounts for 0.22% of the portfolio, ranked #151.

Driehaus Capital Management first reported a position in KNSA in Q3 2023 and has held it in 11 quarters since. 228 funds tracked by Wall St. Rank hold KNSA as of Q1 2026.

  • Driehaus Capital Management held 611,398 shares of Kiniksa Pharmaceuticals worth $29.4M as of Q1 2026.
  • Driehaus Capital Management sold 21,429 Kiniksa Pharmaceuticals shares in Q1 2026, an estimated $949K.
  • Kiniksa Pharmaceuticals made up 0.22% of Driehaus Capital Management's portfolio in Q1 2026, its #151 holding.
  • Driehaus Capital Management first reported a position in Kiniksa Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • 228 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.